
Cross Country Healthcare, Inc. (CCRN) entered a merger agreement on May 7, 2026, to be acquired by Knox Lane in an all-cash deal valued at $437 million.
Knox Lane will acquire all outstanding shares of Cross Country Healthcare common stock for $13.25 per share, representing a premium of 31.06% from the stock’s last close.
Cross Country is a healthcare workforce solutions company that provides staffing, recruitment, workforce management, and consulting services to hospitals and healthcare providers across the U.S. The company operates technology-enabled platforms for managing contingent labor and supplies nurses, allied health professionals, physicians, and other clinical staff on temporary, permanent, and contract assignments.
Knox Lane is a San Francisco-based private equity firm that invests in growth-oriented businesses across the services and consumer sectors. The firm works with portfolio companies on operational improvement, digital transformation, acquisitions, and strategic growth initiatives, and manages approximately $3 billion in assets under management.
The merger is expected to close in the third quarter of 2026.
BofA Securities and Davis Polk & Wardwell are serving as financial and legal advisors to Cross Country Healthcare, respectively, while MTS Health Partners and Kirkland & Ellis are acting as financial and legal advisors to Knox Lane.
In 2024, Cross Country entered a merger with Aya Healthcare for $18.61 per share in cash. That merger was terminated after a year, because the companies were unable to fulfill the expiration of the waiting period under the HSR Act due to the 43-day government shutdown.
Knox Lane is paying 17 times EBITDA for Cross Country Healthcare.
For a more comprehensive look at this M&A transaction, visit the Deal Metrics page here:
Deal Metrics for the acquisition of Cross Country Healthcare, Inc. (CCRN) by Knox Lane
The Deal Metrics page for each merger or acquisition provides a wealth of information, including:
Disclaimer: The information contained in this article is for informational purposes only. Please perform your own due diligence before buying or selling any securities mentioned herein. We do not guarantee the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article